PF-06462700
Phase 3Biologic
PfizerPF-06462700 is one of 46 biologic programs targeting Aplastic Anemia. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
70 competitors in Aplastic Anemia
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Busulfex
Akero TherapeuticsPhase 3
Alkeran
AApotex Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Neoral
NovartisPhase 2
Promacta
GSKPhase 2
Fludara
SanofiPhase 2
Atgam
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-06462700. EMBL-EBI & Wellcome Sanger Institute.
- [4]